Departments of Pathology and Laboratory Medicine (M.K.), University of Calgary, Calgary AB, Canada
Genetic Pathology Evaluation Centre of the Prostate Research Centre (S.E.K., D.G.H., C.B.G.), Departments of Pathology, Vancouver General Hospital and British Columbia Cancer Agency, and Gynecology Tumor Group, British Columbia Cancer Agency, Vancouver BC, Canada
Cheryl Brown Ovarian Cancer Outcomes Unit (J.L.S., K.D.S.), British Columbia Cancer Agency
Departments of Pathology and Laboratory Medicine (J.D.S.), Washington Hospital Center, Washington, DC
This study was funded by the National Cancer Institute of Canada (♯ 017051), the Michael Smith Foundation for Health Research Unit Grant (♯ INRUA006045) to CBG, and by an unrestricted educational grant from sanofiaventis. This study was supported by the Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency. Martin Köbel received fellowship support from Eli Lilly Canada. No funding was received for this study from any of the following organizations: National Institutes of Health (NIH); Wellcome Trust; and Howard Hughes Medical Institute (HHMI).
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.intjgynpathology.com)
Address correspondence and reprint requests to Martin Köbel, MD, Department of Pathology and Laboratory Medicine, University of Calgary, C1150, 1403 29th ST, NW, Foothill Medical Center, Calgary, AB, Canada T2N 2T9. E-mail: [email protected]